Aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants

Pediatric Infectious Disease Journal

Volumn 15, Issue 3, 1996, Pages 209-216

  Rimensberger, Peter C ^a,g   Burek Kozlowska, Anna ^b   Morell, Andreas ^b   Germann, Daniel ^a   Eigenmann, Anne K ^c   Steiner, Felicitas ^d   Burger, René ^e   Kuenzli, Markus ^f   Schaad, Urs B ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Blood Transfusion Service

^c CHILDREN S HOSPITAL   (Switzerland)

^d Children's Hospital   (Ireland)

^e UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^f University Hospital of Geneva ^*  (Switzerland)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

administration; immunotherapy; infants; inhalation; Respiratory syncytial virus

Indexed keywords

IMMUNOGLOBULIN; OXYGEN;

APNEA; ARTICLE; ARTIFICIAL VENTILATION; BRONCHIOLITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PNEUMOTHORAX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; SWITZERLAND; TREATMENT OUTCOME;

AEROSOLS; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CERCOPITHECUS AETHIOPS; HUMANS; IMMUNOGLOBULINS; INFANT; INFANT, NEWBORN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VERO CELLS;

EID: 0029875453     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199603000-00007     Document Type: Article

References (45)

1. Parrot RH, Kim HW, Arrobio JO, et al. Epidemiology of respiratory syncytial virus infection in Washington, DC: II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol 1973;98:289-300.
2. Green M, Brayer AF, Schenkman KA, Wald ER. Duration of hospitalization in previously well infants with respiratory syncytial virus infection. Pediatr Infect Dis J 1989;8:601-5.
3. MacDonald NE, Hall CB, Suffin SO, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982;307:397-400.
4. Moler FW, Khan AS, Meliones JN, Custer JR, Palmisano J, Shope TC. Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. Crit Care Med 1992;20:1406-13.
5. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus in children with bronchopulmonary dysplasia. Pediatrics 1988;82:199-203.
6. Hall CB, Powell K, MacDonald ME, et al. Respiratory syncytial virus infection in children with compromised immune function. N Engl J Med 1986;315:77-81.
7. Navas L, Wang E, De Carvalho V, Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. J Pediatr 1992; 121:348-54.
8. Hall CB, McBride JT, Walsh EE, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection: a randomized double-blind study. N Engl J Med 1983; 308:1443-7.
9. Taber LH, Knight V, Gilbert BE, et al. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics 1983;72:613-8.
10. Barry W, Cockburn F, Cornall R, Price JP, Sutherland G, Vardag A. Ribavirin aerosol for acute bronchiolitis. Arch Dis Child 1986;61:593-7.
11. Groothuis JR, Woodin KA, Katz R, et al. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. J Pediatr 1990;117:792-8.
12. Smith DW, Frankel LR, Mathers LH, Tang ATS, Ariagno RL, Prober CG. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991;325:24-9.
13. Belshe RB, Van Voris LP, Mufson MA. Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J Infect Dis 1982;145:311-19.
14. Tristram DA, Welliver RC, Mohar CK, et al. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis 1993; 167:191-5.
15. Belshe RB, Anderaon EL, Walsh EE. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis 1993;168:1024-9.
16. Portnoy J, Hicks R, Pacheco F, Olson L. Pilot study of recombinant interferon alpha-2a for treatment of infants with bronchiolitis induced by respiratory syncytial virus. Antimicrob Agents Chemother 1988;32:589-91.
17. American Academy of Pediatrics, Committee on Infectious Diseases. Use of ribavirin in the treatment of respiratory syncytial virus infection. Pediatrics 1993;92:501-4.
18. Wheeler JG, Wofford J, Turner RB. Historical cohort evaluation of ribavirin efficacy in respiratory syncytial virus infection. Pediatr Infect Dis J 1993;12:209-13.
19. Carmack MA, Prober CG. Respiratory syncytial virus and ribavirin: quo vadis? Infect Agents Dis 1992;1:99-107.
20. Prince GA, Hemming VG, Horswood RL, Chanock RM. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Vir Res 1985;3:193-206.
21. Prince GA, Horswood RL, Chanock RM. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 1985;55:517-20.
22. Prince GA, Hemming VG, Horswood RL, Baron PA, Chanock RM. Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats. J Virol 1987;61:1851-4.
23. Hemming VG, Prince GA, London WT, Baron PA, Brown R, Chanock RM. Topically administered immunoglobulin reduces pulmonary respiratory syncytial virus shedding in owl monkeys. Antimicrob Agents Chemother 1988;32:1269-70.
24. Piazza FM, Johnson SA, Ottolini MG, et al. Immunotherapy of respiratory syncytial virus infection in cotton rats (Sigmodon fulviventer) using IgG in a small-particle aerosol. J Infect Dis 1992;166:1422-4.
25. Hemming VG, Rodriguez W, Kim HW, et al. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children. Antimicrob Agents Chemother 1987;31:1882-6.
26. Groothuis JR, Levin MJ, Rodriguez W, et al. Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. Antimicrob Agents Chemother 1991;35:1469-73.
27. Groothuis JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993;329:1524-30.
28. Rimensberger PC, Schaad UB. Clinical experience with aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants. Pediatr Infect Dis J 1994;13:328-30.
29. Michaels MG, Serdy C, Barbadora K, Green M, Apalsch A, Wald ER. Respiratory syncytial virus: a comparison of diagnostic modalities. Pediatr Infect Dis J 1992;11:613-6.
30. Miller H, Milk R, Diaz-Mitoma F. Comparison of the VIDAS RSV assay and the Abbott Testpack RSV with direct immunofluorescence for detection of respiratory syncytial virus in nasopharyngeal aspirates. J Clin Microbiol 1993;31:1336-8.
31. Krilov LR, Lipson SM, Barone SR, Kaplan MH, Ciamician Z, Harkness SH. Evaluation of a rapid diagnostic test for respiratory syncytial virus (RSV): potential for bedside diagnosis. Pediatrics 1994;93:903-6.
32. Ahluwalia G, Embree J, McNicol P, Law B, Hammond GW. Comparison of nasopharyngeal aspirate and nasopharyngeal swab specimens for respiratory syncytial virus diagnosis by cell culture, indirect immunofluorescence assay, and enzymelinked immunosorbent assay. J Clin Microbiol 1987;25: 763-7.
33. O'Callaghan C, Milner AD, Swarbrick A. Paradoxical deterioration in lung function after nebulised salbutamol in wheezy infants. Lancet 1986;2:1424-5.
34. Soto ME, Sly PD, Uren E, Taussig LM, Landau LI. Bronchodilator response during acute viral bronchiolitis in infancy. Pediatr Pulmonol 1985;2:85-90.
35. Klassen TP, Rowe PC, Sutcliffe T, Rapp L, McDowell IW, Li MM. Randomized tried of salbutamol in acute bronchiolitis. J Pediatr 1991;118:807-11.
36. Schöni MH, Krämer R. Osmolality changes in nebulizer solutions. Eur Respir J 1989;2:887-92.
37. Rimensberger PC, Roth C. Physical properties of aerosolized immunoglobulin for inhalation therapy in infants. J Aerosol Med 1995;8:255-62.
38. Bierman CW, Pierson WE. The pharmacologic management of status asthmaticus in children. Pediatrics 1974;54:245-7.
39. Sarkkinen HK, Halonen PE, Arstila PP, Salmi AA. Detection of respiratory syncytial, parainfluenza type 2, and adenovirus antigens by radioimmunoassay and enzyme immunoassay on nasopharyngeal specimens from children with acute respiratory disease. J Clin Microbiol 1981;13:258-65.
40. Becquemin MH, Yu CP, Roy M, Bouchikhi A. Total deposition of inhaled particles related to age: comparison with age-dependent model calculations. Radiat Prot Dosim 1991;38:167-74.
41. Schiller-Scotland CF, Hlava R, Gebhart J, Woenne R, Heyder J. Total deposition of aerosol particles in the respiratory tract of children during spontaneous and controlled breathing. J Aerosol Sci 1992;23:457-60.
42. Waris M. Pattern of respiratory syncytial virus epidemics in Finland: two-year cycles with alternating prevalence of Groups A and B. J Infect Dis 1991;163:464-9.
43. Hendry RM, Talis AL, Godfrey E, Anderson LJ, Fernie BF, McIntosh K. Concurrent circulation of antigenically distinct strains of repiratory syncytial virus during community outbreaks. J Infect Dis 1986;153:291-7.
44. Sullivan B. RSV and ribavirin. Pediatr Infect Dis J 1986;5: 605-6.
45. Englund JA, Piedra PA, Ahn Y, Gilbert BE, Hiatt P. High-dose, short duration ribavirin aerosol therapy compared with standard ribavirin therapy in children suspected respiratory syncytial virus infection. J Pediatr 1994;125:635-41.